Wesley Self Archive — Page 3 of 4
-
September 3, 2020
COVID infections in health workers often go undetected: study
Many COVID-19 infections among health care workers go undetected, likely because many people infected with SARS-CoV-2, the virus that causes COVID-19, have mild or no symptoms, a study led by Vanderbilt University Medical Center’s Wesley Self, MD, MPH, shows. -
July 16, 2020
Investigational glaucoma drug studied to prevent respiratory distress in COVID-19 patients
Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. -
July 9, 2020
About half of health care workers positive for COVID-19 by serology have no symptoms
The IVY Research Network has completed initial studies evaluating the epidemiology of COVID-19 in health care workers and patients. -
June 21, 2020
Major U.S. trial closes showing no benefit for hydroxychloroquine in COVID-19
The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm. -
April 8, 2020
Study launched to test hydroxychloroquine as treatment for COVID-19
-
October 9, 2019
Vaccine study seeks to halt flu’s most severe side effects
Vanderbilt University Medical Center is leading a multicenter national study to evaluate the effectiveness of the influenza vaccine for preventing the flu’s most serious side effects — admission to an intensive care unit (ICU), organ failure and death. -
February 27, 2018
Saline use on decline at Vanderbilt following landmark studies
Vanderbilt University Medical Center is encouraging its medical providers to stop using saline as intravenous fluid therapy for most patients, a change provoked by two companion landmark studies released Feb. 27 that are anticipated to improve survival and decrease kidney complications.